Technical analysis of Genenta Science S.p.A. (GNTA): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter.
Price Performance
| 1 month | -36.64% |
| 3 months | -55.88% |
| Year-to-date | -50.25% |
| 1 year | -76.09% |
| 3 years | -86.50% |
52-Week Range
| 52-week High | $10.00 |
| 52-week Low | $0.55 |
| Avg Volume (90d) | 1.0M |
Technical Indicators
| SMA 50 | $1.26 |
| SMA 200 | $1.18 |
| Beta | 0.71 |
| 30-day Volatility (annualised) | 73.5% |
| Price vs SMA 50 | -41.0% |
| Price vs SMA 200 | -37.1% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.57 | |
| 2025-11 | $2.01 | -21.8% |
| 2025-12 | $1.49 | -25.9% |
| 2026-01 | $0.99 | -33.8% |
| 2026-02 | $0.99 | +0.4% |
| 2026-03 | $0.67 | -32.2% |
| 2026-04 | $0.71 | +5.8% |
| 2026-05 | $1.03 | +44.8% |
| 2026-06 | $1.84 | +78.6% |
| 2026-07 | $1.49 | -19.0% |
| 2026-08 | $1.02 | -31.5% |
| 2026-09 | $0.74 | -27.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $0.74 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | IT |
Valuation Ratios
| Price / Book | 0.64 |
| EV / EBITDA | -3.14 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.35 |
| Current Ratio | 14.16 |